In vivo and in vitro toxicodynamic analyses of new quinolone- and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1091-1097

  Kita, Hideki ^a   Matsuo, Hirotami ^a   Takanaga, Hitomi ^a   Kawakami, Junichi ^b   Yamamoto, Koujirou ^b   Iga, Tatsuji ^b   Naito, Mikihiko ^c   Tsuruo, Takashi ^c   Asanuma, Atsushi ^d   Yanagisawa, Keiji ^d   Sawada, Yasufumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TSURUMI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANTIINFLAMMATORY AGENT; ENOXACIN; FELBINAC; FLURBIPROFEN; KETOPROFEN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; MALE; MATHEMATICAL MODEL; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TOXICOKINETICS; XENOPUS;

EID: 0032907202     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1091     Document Type: Article

References (32)

1. Anatasio, G. D., D. Menscer, and J. M. Little. 1988. Norfloxacin and seizures. Ann. Intern. Med. 109:169-170.
2. Asanuma, A., T. Horikoshi, K. Yanagisawa, K. Anzai, and S. Goto. 1987. The distribution of GABA and glycine response in the mouse brain using Xenopus oocytes. Neurosci. Lett. 76:87-90.
3. Barnett, G., J. Segura, R. Torre, and M. Carbo. 1990. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition. Eur. J. Clin. Pharmacol. 39:63-69.
4. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
5. Frost, R. W., J. T. Lettieri, A. Noe, E. C. Shamblen, and K. Lasseter. 1989. Effect of aluminum hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability. Clin. Pharmacol. Ther. 45:165.
6. Gessner, P. K., and B. E. Cabana. 1970. A study of the interaction of the hypotic effects and of the toxic effects of chloral hydrate and ethanol. J. Pharmacol. Exp. Ther. 174:247-259.
7. Hori, S., J. Shimada, J. Saito, M. Matsda, and T. Miyahara. 1989. Comparison of the inhibitory effects of new quinolones on g-aminobutyric acid receptor binding in presence of antiinflammatory drugs. Rev. Infect. Dis. 11(Suppl. 5):S1397-S1398.
8. Horikoshi, T., A. Asanuma, K. Yanagisawa, K. Anzai, and S. Goto. 1988. Taurine and β-alanine act on both GABA and glycine receptors in Xenopus oocyte injected with mouse messenger RNA. Mol. Brain Res. 4:97-105.
9. Katagiri, Y., K. Naora, N. Ichikawa, M. Hayashibara, and K. Iwamoto. 1988. Simultaneous determination of ofloxacin, fenbufen and felbinac in rat plasma by high-performance liquid chromatography. J. Chromatogr. 431: 135-142.
10. Katagiri, Y., K. Naora, N. Ichikawa, M. Haytashibara, and K. Iwamoto. 1989. High-performance liquid chromatographic procedure for the simultaneous determination of norfloxacin, fenbufen and felbinac in rat plasma. Chem. Pharm. Bull. 37:2858-2860.
11. A receptor-mediated current responses by enoxacin (new quinolone) and felbinac (non-steroidal anti-inflammatory drug) in Xenopus oocyte injected with mouse-brain messenger RNA. Biol. Pharm. Bull. 16:726-728.
12. A receptor-mediated response and its potentiation with felbinac in Xenopus oocytes injected with mouse-brain mRNA: correlation with convulsive potency in vivo. Toxicol. Appl. Pharmacol. 145:246-254.
13. Loewe, S. 1953. The problem of synergism and antagonism of combined drugs. Arzneim. Forsh. 3:285-290.
14. Maesen, F. P. V., J. P. Teengs, C. Baur, and B. I. Davies. 1984. Quinolones and raised plasma concentrations of theophylline. Lancet ii:530.
15. Miyama, T., H. Takanaga, H. Matsuo, K. Yamano, K. Yamamoto, T. Iga, M. Naito, T. Tsuruo, H. Ishizuka, Y. Kawahara, and Y. Sawada. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob. Agents Chemother. 42:1738-1744.
16. Nakamura, R., T. Yamaguchi, Y. Sekine, and M. Hashimoto. 1983. Determination of a new antibacterial agent (AT-2266) and its metabolites in plasma and urine by high-performance liquid chromatography. J. Chromatogr. 278:321-328.
17. Paton, J. H., and D. S. Reeves. 1991. Clinical features and management of adverse effects of quinolone antibacterials. Drug Safety 6:8-27.
18. Polk, R. E., D. P. Healy, J. Sahai, L. Drwal, and E. Racht. 1989. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob. Agents Chemother. 33:1841-1844.
19. Sano, M., K. Kawakatsu, I. Yamamoto, M. Takeyama, H. Yamashina, and M. Goto. 1989. Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans. Eur. J. Clin. Pharmacol. 36:323-324.
20. Schwarts, M. T, and J. F. Calvert. 1990. Potential neurologic toxicity related to ciprofloxacin. Ann. Pharmacother. 24:138-140.
21. Staib, A. H., W. Stille, G. Dietlein, P. M. Shah, S. Mieke, and C. Beer. 1987. Interaction between quinolones and caffeine. Drugs 34(Suppl. 1):170-174.
22. Stille, W., S. Harder, S. Mieke, C. Beer, P. M. Shah, K. Frech, and A, H. Staib. 1987. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J. Antimicrob. Chemother. 20:729-734.
23. Takedomi, S., H. Matsuo, K. Yamano, K. Yamamoto, T. Iga, and Y. Sawada. 1998. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug Metab. Dispos. 26:318-323.
24. Tallarida, R. J. 1990. Further characterization of a control model for ligand-receptor interaction: phase plane geometry, stability and oscillation. Ann. Biomed. Eng. 18:671-684.
25. Tallarida, R. J. 1992. Statistical analysis of drug combinations for synergism. Pain 49:93-97.
26. Tallarida, R. J., F. Porreca, and A. Cowan. 1986. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 45:947-961.
27. Tatsuta, T., M. Naito, T. Oh-hara, I. Sugawara, and T. Tsuruo. 1992. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267:20383-20391.
28. Tsuji, A., H. Sato, Y. Kume, I. Tamai, E. Okezaki, O. Nagata, and H. Kato. 1988. Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob. Agents Chemother. 32:190-194.
29. Tsuji, A., H. Sato, E. Okezaki, O. Nagata, and H. Kato. 1988. Effect of the anti-inflammatory agent fenbufen on the quinolone-induced inhibition of γ-aminobutyric acid binding to rat brain membranes in vitro. Biochem. Pharmacol. 37:4408-4411.
30. Wijnands, W. J. A., C. L. A. Herwaarden, and T. B. Vree. 1984. Enoxacin raises plasma theophylline concentration. Lancet ii:108-109.
31. Wijnands, W. J. A., T. B. Vree, and C. L. A. Herwaarden. 1986. The influence of quinolone derivatives on theophylline clearance. Br. J. Clin. Pharmacol. 22:677-683.
32. Yamaoka, K., Y. Tanigawara, T. Nakagawa, and T. Uno. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmaco.-Dyn. 4:879-885.